[1]Bolli,MartinH.;Boss,Christoph;Binkert,Christoph;Buchmann,Stephan;Bur,Daniel;Hess,Patrick;Iglarz,Marc;Meyer,Solange;Rein,Josiane;Rey,Markus;Treiber,Alexander;Clozel,Martine;Fischli,Walter;Weller,Thomas[JournalofMedicinalChemistry,2012,vol.55,#17,p.7849-7861]
[2]CurrentPatentAssignee:LAURUSLABSLIMITED-WO2017/93903,2017,A1
[3]Jagtap,KunalM.;Niphade,NavnathC.;Gaikwad,ChandrashekharT.;Shinde,GorakshanathB.;Toche,RaghunathB.;Joshi,DivyeshR.;Mathad,VijayavitthalT.[MonatsheftefurChemie,2018,vol.149,#3,p.653-661]
[1]Bolli,MartinH.;Boss,Christoph;Binkert,Christoph;Buchmann,Stephan;Bur,Daniel;Hess,Patrick;Iglarz,Marc;Meyer,Solange;Rein,Josiane;Rey,Markus;Treiber,Alexander;Clozel,Martine;Fischli,Walter;Weller,Thomas[JournalofMedicinalChemistry,2012,vol.55,#17,p.7849-7861]
[2]CurrentPatentAssignee:LAURUSLABSLIMITED-WO2017/93903,2017,A1
[3]Jagtap,KunalM.;Niphade,NavnathC.;Gaikwad,ChandrashekharT.;Shinde,GorakshanathB.;Toche,RaghunathB.;Joshi,DivyeshR.;Mathad,VijayavitthalT.[MonatsheftefurChemie,2018,vol.149,#3,p.653-661]
[1]JournalofMedicinalChemistry,2012,vol.55,p.7849-7861
[2]Patent:WO2017/93903,2017,A1
[3]MonatsheftefurChemie,2018,vol.149,p.653-661
[1]JournalofMedicinalChemistry,2012,vol.55,p.7849-7861
[2]Patent:WO2017/93903,2017,A1
[3]MonatsheftefurChemie,2018,vol.149,p.653-661
[1]JournalofMedicinalChemistry,2012,vol.55,p.7849-7861
[2]Patent:WO2015/121397,2015,A1
[3]Patent:WO2015/121397,2015,A1
[4]Patent:WO2016/203489,2016,A1
[5]Patent:WO2016/203489,2016,A1
[6]Patent:WO2017/33016,2017,A1
[7]Patent:WO2017/93903,2017,A1
[8]Patent:WO2017/191565,2017,A1
[9]MonatsheftefurChemie,2018,vol.149,p.653-661
Title: From the Cover: MechanisticInsights in Cytotoxic and Cholestatic Potential of the Endothelial Receptor Antagonists Using HepaRG Cells.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20170601
Title: Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension.
Journal: Reproductive toxicology (Elmsford, N.Y.) 20150815
Title: Pathways in pulmonary arterial hypertension: the future is here.
Journal: European respiratory review : an official journal of the European Respiratory Society 20121201
Title: Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.
Journal: Life sciences 20121015
Title: The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
Journal: Journal of medicinal chemistry 20120913
Title: Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.
Journal: The AAPS journal 20120301
Title: Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
Journal: PloS one 20120101
Title: Macitentan: entry-into-humans study with a new endothelin receptor antagonist.
Journal: European journal of clinical pharmacology 20111001
Title: Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.
Journal: Neoplasia (New York, N.Y.) 20110201
Title: Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
Journal: Current opinion in investigational drugs (London, England : 2000) 20100901
Title: Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20091105
Title: Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
Journal: The Journal of pharmacology and experimental therapeutics 20081201
Title: Corallo C, et al. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Res Ther. 2016 Oct 6;18(1):228.
Title: Sen S, et al. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist. Life Sci. 2012 Apr 13.
Title: Bruderer S, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J. 2012 Mar;14(1):68-78.
Title: Kim SJ, et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.Transl Oncol. 2012 Feb;5(1):39-47.
